BiotechTube

Romiplostim

Phase 3Completed
2 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Thrombocytopenia in Pediatric Subjects With Immune Idiopathic Thrombocytopenic Purpura ITP

Conditions

Thrombocytopenia in Pediatric Subjects With Immune Idiopathic Thrombocytopenic Purpura ITP

Trial Timeline

Dec 30, 2009 → Jan 12, 2017

NCT ID
NCT01071954

About Romiplostim

Romiplostim is a phase 3 stage product being developed by Amgen for Thrombocytopenia in Pediatric Subjects With Immune Idiopathic Thrombocytopenic Purpura ITP. The current trial status is completed. This product is registered under clinical trial identifier NCT01071954. Target conditions include Thrombocytopenia in Pediatric Subjects With Immune Idiopathic Thrombocytopenic Purpura ITP.

What happened to similar drugs?

2 of 20 similar drugs in Thrombocytopenia in Pediatric Subjects With Immune Idiopathic Thrombocytopenic Purpura ITP were approved

Approved (2) Terminated (2) Active (16)
✅Standard heparin (UFH) versus certoparin (LMWH)NovartisApproved
✅romiplostimAmgenApproved
🔄avatrombopag (lower baseline platelet count) + placebo (lower baseline platelet count) + avatrombopag (higher baseline platelet count) + placebo (higher baseline platelet count)EisaiPhase 3
🔄avatrombopag (lower baseline platelet count) + placebo (lower baseline platelet count) + avatrombopag (higher baseline platelet count) + placebo (higher baseline platelet count)EisaiPhase 3
🔄Avatrombopag + Placebo + Standard of careEisaiPhase 3
🔄Romiplostim + PlaceboKyowa KirinPhase 3
🔄Hetrombopag Olamine + Hetrombopag Olamine ；Hetrombopag Olamine PlaceboJiangsu Hengrui MedicinePhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (15)

NCT IDPhaseStatus
NCT04673266Phase 2Active
NCT04478227Phase 1Completed
NCT04478123Phase 2Completed
NCT03362177Phase 3Completed
NCT03343847Phase 3Withdrawn
NCT02279173Phase 3Completed
NCT02052882Phase 2Completed
NCT01516619Phase 2Completed
NCT01143038Phase 2Completed
NCT01071954Phase 3Completed
NCT00907478ApprovedCompleted
NCT00303472Phase 2Completed
NCT00508820Phase 3Completed
NCT00116688Phase 3Completed
NCT00117143Phase 1/2Completed

Competing Products

20 competing products in Thrombocytopenia in Pediatric Subjects With Immune Idiopathic Thrombocytopenic Purpura ITP

See all competitors
ProductCompanyStageHype Score
Pirtobrutinib + PlaceboEli LillyPhase 1/2
39
Anti-(integrin beta-3) human monoclonal antibodyRallybioPhase 2
17
Placebo + LusutrombopagShionogiPhase 2
27
LusutrombopagShionogiPhase 2
27
Avatrombopag + Avatrombopag + PlaceboEisaiPhase 2
35
avatrombopagEisaiPhase 1
29
E5501 + Drug: E5501EisaiPhase 1
29
avatrombopag (lower baseline platelet count) + placebo (lower baseline platelet count) + avatrombopag (higher baseline platelet count) + placebo (higher baseline platelet count)EisaiPhase 3
40
avatrombopag + PlaceboEisaiPhase 2
35
Avatrombopag + Placebo + Pegylated interferon (PEG-IFN) + Telaprevir + RibavirinEisaiPhase 2
35
avatrombopag (lower baseline platelet count) + placebo (lower baseline platelet count) + avatrombopag (higher baseline platelet count) + placebo (higher baseline platelet count)EisaiPhase 3
40
Avatrombopag + Placebo + Standard of careEisaiPhase 3
40
RomiplostimKyowa KirinPhase 1/2
32
Romiplostim + PlaceboKyowa KirinPhase 3
40
Romiplostim (AMG-531)Kyowa KirinPhase 2
35
Romiplostim and danazolKyowa KirinPhase 2
31
ONO-7746Ono PharmaceuticalPhase 1
21
Hetrombopag OlamineJiangsu Hengrui MedicinePhase 1
29
Hetrombopag Olamine + Hetrombopag Olamine ；Hetrombopag Olamine PlaceboJiangsu Hengrui MedicinePhase 3
47
Hetrombopag OlamineJiangsu Hengrui MedicinePhase 2
42